Skip to Content
Søg Menu

Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

/ Jan Andreasen
NBCNBrystcancer
Kirsten Marie Woolpert

SABCS 2025: Patterns of Opioid Use Among Breast Cancer Survivors

/ Kirsten Marie Woolpert
NBCNSABCS25Brystcancer Play the Video
Sandra Jensen

Metastatic Deposit Size as a Predictor of Axillary Disease After Neoadjuvant Chemotherapy

/ Sandra Jensen
NBCNBrystcancer Play the Video

HER2-negative Breast Cancer – A Pathologist’s Perspective

/ Gilead
Brystcancer
Peeter Karihtala

The Clinical Value of Immuno-Oncological Treatments in Early Breast Cancer

/ Peeter Karihtala
NBCNOnkologiapäivät 2025Brystcancer Play the Video

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
ESMO25NBCNBrystcancer Play the Video
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
ESMO25NBCNBrystcancer Play the Video

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
ESMO25NBCNBrystcancer

Ph.d.: Real-world data for adjuverende behandling af T1abN0 brystkræft

/ Christina Marie Schiøttz Hassing
NBCNBrystcancer Play the Video
Alan Celik

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

/ Alan Celik
NBCNBrystcancer Play the Video
Hent flere
Back to top